The possible role of myocardial biopsy in systemic sclerosis

Rheumatology

Volumn 39, Issue 6, 2000, Pages 674-679

  Liangos, O ^a   Neure, L ^a   Kuhl U ^a   Pauschinger, M ^a   Sieper, J ^a   Distler, A ^a   Schwimmbeck, P L ^a   Braun, J ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN;

ADULT; ARTICLE; CARDIOMYOPATHY; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DYSPNEA; FEMALE; FIBROBLAST; FIBROSIS; HEART DISEASE; HEART MUSCLE BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; INFLAMMATION; MYOCARDITIS; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; T LYMPHOCYTE SUBPOPULATION;

EID: 0033925140     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.6.674     Document Type: Article

References (30)

1. Janosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zuckner J. Heart disease in systemic sclerosis. Semin Arthritis Rheum 1989;19:191-200.
2. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin North Am 1996;22:841-60.
3. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;298:139-48.
4. Follansbee WP, Curtiss EI, Medsger TA Jr, Steen VD, Uretsky BF, Owens GR et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984;310:142-8.
5. Candell-Riera J, Armadans-Gil L, Simeon CP, Castell-Conesa J, Fonollosa-Pla V, Garcia-del-Castillo H et al. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum 1996;39:1138-45.
6. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996;22:861-78.
7. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). Am J Med 1969;46:428-40.
8. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive sclerosis. Circulation 1976;53:483-90.
9. Alexander EL, Firestein GS, Weiss JL, Heuser RR, Leitl G, Wagner HN et al. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 1986;105:661-8.
10. Siegel RJ, O'Connor B, Mena I, Criley JM. Left ventricular function at rest and during Raynaud's phenomenon in patients with scleroderma. Am Heart J 1984;108:1469 76.
11. Nitenberg A, Foult JM, Kahan A, Perennec J, Devaux JY, Menkes CJ et al. Reduced coronary flow and resistance reserve in primary scleroderma myocardial disease. Am Heart J 1986;112:309 15.
12. Valentini G, Vitale DF. Giunta A, Maione S, Gerundo G, Arnese M et al. Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve. Ann Rheum Dis 1996;55:455 60.
13. Saalbach A, Anderegg U, Bruns M, Schnabel E, Herrmann K, Haustein UF. Novel fibroblast-specific monoclonal antibodies: properties and specificities. J Invest Dermatol 1996;106:1314-9.
14. Saalbach A, Aust G, Haustein UF, Anderegg U. The fibroblast-specific MAbAS02: a novel tool for detection and elimination of human fibroblasts. Cell Tissue Res 1997;290:593-9.
15. Byers RJ, Marshall DAS, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis 1997;56:393-4.
16. Martinez-Taboada V, Olalla J, Blanco R, Armona J, Sueiro JF, Rodriguez-Valverde V. Malignant ventricular arrhythmia in systemic sclerosis controlled with an implantable cardioverter defibrillator. J Rheumatol 1994;21:2166 7.
17. Clemson BS, Miller WR, Luck JC, Feriss JA. Acute myocarditis in fulminant systemic sclerosis. Chest 1992;101:872-4.
18. Follansbee WP, Miller TR, Curtiss EI, Oric JE, Bernstein RL, Kiernan JM et al. A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol 1990;17:656 62.
19. Kühl U, Seeberg M, Noutsias M, Schultheiss HP. Immunohistochemical analysis of the chronic inflammatory process in dilated cardiomyopathy. Br Heart J 1995;75:295 300.
20. Baraldi-Junkins C, Levin HR, Kasper EK, Rayburn BK, Herskowitz A, Baughman KL. Complications of endomy-ocardial biopsy in heart transplant recipients. J Heart Lung Transplant 1993;12:63 7.
21. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971;75:369 76.
22. Strehlow D, Korn J. Biology of the scleroderma fibroblast. Curr Opin Rheumatol 1998;10:572 8.
23. Medsger TA. Treatment of systemic sclerosis. Ann Rheum Dis 1991;50(suppl. 4):877 86.
24. Pope JE. Treatment of systemic sclerosis. Rheum Dis Clin North Am 1996;22:893-907.
25. Kahan A, Devaux JY, Amor B, Menkes CJ, Weber S, Nitenberg A et al. Nifedipin and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 1986;314:1397 1402.
26. Geirsson AJ, Danielsen R, Petursson E. Left ventricular myocardial perfusion and function in systemic sclerosis before and after diltiazem treatment. Scand J Rheumatol 1996;25:317-20.
27. Steen VD, Medsger TA Jr, Rodnan GP. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982;97:652 9.
28. Muers M, Stokes W. Treatment of scleroderma heart by D-penicillamine. Br Heart J 1976;38:864-7.
29. Linz W, Wiemer G, Schaper J, Zimmermann R, Nagasawa K, Gohlke P et al. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol Cell Biochcm 1995;147:89-97.
30. Black CM, Halkier-Sorensen L, Belch JJ, Ullman S, Madhok R. Smit AJ et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998;37:952 60.